Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Beats Estimates By $0.13 EPS

Dianthus Therapeutics (NASDAQ:DNTH) issued its quarterly earnings data on Wednesday. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.13, FiscalAI reports. The firm had revenue of $1.21 million during the quarter, compared to analyst estimates of $0.46 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.

Dianthus Therapeutics Trading Up 3.8%

Shares of NASDAQ DNTH traded up $3.11 during midday trading on Wednesday, reaching $85.81. The company had a trading volume of 1,679,417 shares, compared to its average volume of 948,135. The business’s 50-day simple moving average is $91.11 and its 200 day simple moving average is $85.18. The stock has a market cap of $4.70 billion, a P/E ratio of -20.68 and a beta of 1.47. Dianthus Therapeutics has a 1 year low of $32.42 and a 1 year high of $117.88.

Analyst Ratings Changes

Several research analysts recently weighed in on DNTH shares. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Roth Capital started coverage on Dianthus Therapeutics in a research report on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price on the stock. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They issued an “overweight” rating and a $135.00 price target for the company. Citigroup started coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a “buy” rating and a $156.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $158.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $128.54.

Insider Buying and Selling at Dianthus Therapeutics

In other news, CAO Edward Carr sold 20,000 shares of the business’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total transaction of $2,027,600.00. Following the sale, the chief accounting officer directly owned 20,000 shares of the company’s stock, valued at $2,027,600. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anne McGeorge sold 7,750 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the transaction, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 242,429 shares of company stock valued at $26,118,913. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.